A
Amitabha Mazumder
Researcher at New York University
Publications - 146
Citations - 10381
Amitabha Mazumder is an academic researcher from New York University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 40, co-authored 146 publications receiving 9842 citations. Previous affiliations of Amitabha Mazumder include New York Medical College & Westchester Medical Center.
Papers
More filters
Journal ArticleDOI
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
TL;DR: Evidence is presented that the LAK system is a phenomenon distinct from either NK or CTL systems that probably accounts for a large number of reported nonclassical cytotoxicities and may be functional in immune surveillance against human solid tumors.
Journal ArticleDOI
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G. Richardson,Edie Weller,Sagar Lonial,Andrzej Jakubowiak,Sundar Jagannath,Noopur Raje,David Avigan,Wanling Xie,Irene M. Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Robin Joyce,Jonathan L. Kaufman,Deborah Doss,Diane Warren,Laura E. Lunde,Sarah Kaster,Carol Delaney,Teru Hideshima,Constantine S. Mitsiades,Robert Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +24 more
TL;DR: Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal Article
Lysis of Fresh and Cultured Autologous Tumor by Human Lymphocytes Cultured in T-Cell Growth Factor
TL;DR: It is demonstrated that peripheral lymphoid cells grown in TCGF can be lytic for autologous cultured and autOLOGous fresh tumor compared to the lysis of fresh autologOUS peripheral blood lymphocytes.
Journal ArticleDOI
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
Elizabeth A. Grimm,Keith M. Ramsey,Amitabha Mazumder,Debra J. Wilson,Julie Y. Djeu,Steven A. Rosenberg +5 more
TL;DR: While the cell(s) responsible for activation and expression of LAK activity have some common features with the classic T cell-mediated CTL and NK cell systems, the LAK precursor cells are clearly distinct as determined by phenotype analysis using monoclonal antibodies and complement, and at present must be classified as a “null” cell.